On October 8, 2026, Cantor Fitzgerald reiterated its Overweight rating on Eupraxia Pharmaceuticals (NASDAQ: EPRX). The firm maintained its $19.00 price target. At a current trading price of $7.78, that target represents potential upside of more than 140%. Cantor noted that Eupraxia has rapidly gained investor attention this year.
The reaffirmation comes ahead of an anticipated interim analysis of Eupraxia's treatment for eosinophilic esophagitis. H.C. Wainwright, Wedbush, and Stifel have also issued Buy or Outperform ratings. Their price targets range from $11.00 to $25.00. The analysts cited positive trial data for Eupraxia's EP-104GI treatment.